AbbVie Gets Humira Erosion Right, But Skyrizi/Rinvoq Disappoint Investors

 
• By Joseph Haas
  
Sales decline
Humira suffered significant biosimilar erosion during Q1, but it was in line with projections • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business